CA153、CA125、CEA联合检测在乳腺癌诊断中的应用价值

目的探讨CA153、CA125、CEA三项肿瘤标志物联合检测对乳腺癌早期诊断和鉴别诊断的应用价值。方法采用电化学发光免疫分析技术检测68例乳腺癌患者、38例乳腺良性病变者、30例健康人的血清中CA153、CA125、CEA含量,并分析阳性检出率和敏感性、特异性。结果乳腺癌患者血清CA153、CA125、CEA的含量高于健康人和良性病变者（均P〈0.01）。三项指标联合检测的敏感性和特异性为70.6%和84.9%,乳腺癌组与健康人及乳腺良性肿块组有显著性差异（P〈0.01）。结论 CA153、CA125、CEA三项肿瘤标志物联合检测能提高乳腺癌早期诊断的敏感性且有较好的特异性,具有一定的临床应用价值。     

乳腺癌患者血浆CA15—3的表达及意义

2009年全世界共诊断出新增乳腺癌患者超过120万例,因此致死的患者达到50万例。目前治疗乳腺癌最有效的手段仍是手术治疗,但术后患者的生活质量和身心健康都会受到严重影响。随着分子生物学的研究进展，各肿瘤生物分子标志物的发现．为肿瘤的早期发现和疗效判断开创了新局面。糖类抗原CA15—3由腺细胞表面黏蛋白MUC-1裂解析出，     

血清CA15-3对于判断乳腺癌预后的临床意义

目的　探讨血清CA15 3检测对于判断乳腺癌转移的临床意义。方法　动态监测 14 5例乳腺癌患者的CA15 3水平 ,分析其与复发转移和治疗效果的关系 ,CA15 3检测采用电化学发光免疫分析法。结果　发生复发转移的乳腺癌患者CA15 3水平明显高于无复发转移者 (χ2 =2 7 86 5 ,P <0 0 1) ,多发转移的患者CA15 3水平高于单发转移者 (χ2 =6 6 6 6 ,P <0 0 1) ,综合治疗有效的复发转移患者CA15 3水平明显下降。结论　血清CA15 3检测对于判断乳腺癌的转移和治疗效果有一定意义。     

在确定乳腺癌的组织病理学传统预后因素中术前血浆CA15-3和CEA的意义

重点评估术前血浆CA15—3和癌胚抗原(CEA)的预后判断意义，取土耳其安卡拉培训医院第三外科临床收治的29例女性乳腺癌病例(平均年龄43岁)进行分析，均为浸润性导管癌。统计CEA、CA15—3值与传统的组织病理学预后因素，包括水平I、Ⅱ淋巴结转移数、Bloom-Richurdosn肿瘤组织学分级、淋巴浸润、     

14-3-3θ在乳腺癌中的表达和意义

目的：研究14-3-3θ在乳腺癌组织中的表达及其临床意义。方法：应用S-P免疫组化法检测14-3-3θ在66例乳腺癌组织中的表达情况。结果：14-3-3θ在乳腺癌组织中的表达与患者年龄、原发肿瘤大小、临床分期、孕激素受体（progesteronereceptor,PR）、原癌基因人类表皮生长因子受体2（human epidermalgrowth factor receptor-2,Her-2）无关（P〉0.05）;在腋窝淋巴结转移组14-3-3θ阳性率明显高于无转移组（P〈0.05）;在雌激素受体（estrogen receptor,ER）阴性乳腺癌组织中的阳性率远高于ER阳性组（P〈0.01）。结论：14-3-3θ与乳腺癌的转移和预后存在一定的相关性。     

转录因子T-bet与GATA结合蛋白3的比值在大鼠肺移植急性排斥反应中的mRNA表达及其意义

目的 探讨T-bet(T-box expression in T cells)和GATA结合蛋白3(GATA-3)在大鼠肺移植急性排斥反应中的mRNA表达及其意义.方法 建立同种异体大鼠肺移植模型,实验分为正常对照组(n=5只)、同种异体移植3 d组(n=4只)和5 d组(n=6只),用实时荧光定量逆转录-聚合酶链反应(RT-PCR)法,检测移植后肺组织中T-bet和GATA-3的mRNA表达.结果 实时荧光定量RT-PCR检测T-bet和GATA-3的扩增效率为78%～85%,批内和批间实验循环阈值(Ct)变化均＜0.15.与止常对照和右侧非移植肺比较,同种异体移植术后3 d组,T-bet和GATA-3无显著性改变,但其比值明显高于右侧肺;同种异体移植术后5 d组,T-bet表达增高(9.31拷贝/106 18 S拷贝),但差异无统计学意义(P＞0.05),GATA-3表达下降(0.88拷贝/105 18 S拷贝),T-bet/GATA3的比值增高(1.12),差异均有统计学意义(P＜0.05).结论 实时荧光定量RT-PCR检测T-bet和GATA-3结果准确可靠.在急性排斥反应中,T-bet表达升高,GATA-3表达降低,其中GATA-3的表达起主导作用.T-bet/GATA-3的比值比单独检测T-bet或GATA-3更能客观地评价大鼠肺移植急性排斥反应.     

CD15抗原和CD44V6蛋白在乳腺癌中的表达及意义

细胞黏附分子(cellular adhesion molecules,CAMs)是一大类位于细胞表面的糖蛋白分子,在恶性肿瘤的发生发展过程大多伴有CAMs或其配基的变化,CD15抗原和CD44V6蛋白均为其家族成员,它们在乳腺良恶性病变中有不同表达。本研究通过检测CD15抗原和CD44V6蛋白在乳腺癌及乳腺增生组织     

乳腺癌复发/转移部位及生存与血清癌抗原15-3、碱性磷酸酶水平的关系

目的 探讨乳腺癌复发/转移部位及生存与血清癌抗原15-3(CA153)、碱性磷酸酶水平(ALP)的关系.方法 分析192例晚期乳腺癌患者的血清CA153、ALP水平.结果 血清CA153、ALP水平的均值及联合检测阳性率与转移部位无明显相关;单纯骨骼/软组织/肝脏/肺脏转 移组,CA153阳性率均高于ALP(52.2％比14.3％、64.4％比7.0％、83.3％比0.0％、69.2％比0.0％),差异有统计学意义(P＜0.05);不同病理分子分型的CA153、ALP单独及联合检测阳性率差异无统计学意义(P ＞0.05);CA153阈值为17 U/ml时,阴性组中位无疾病进展时间(PFS)为12.0个月,阳性组为10.0个月,差异有统计学意义(P ＜0.05);ALP水平对PFS无明显影响.结论 血清CA153、ALP水平对乳腺癌复发/转移部位可能有一定的提示意义,与病理分子分型无明显相关,CA153水平影响晚期乳腺癌患者的生存.     

CA15-3和CA-125联合检测乳腺癌44例

乳腺癌的早期诊断是近年来的重要课题。有研究表明,很多血清肿瘤标志物与乳腺癌的发生具有相关性,本研究选择敏感性和特异性相对较高的CA15-3和CA-125进行联合检测．     

Cohort study of women at risk for breast cancer and gross cystic disease

BACKGROUND: Gross cystic disease (GCD) is a common benign breast condition. Previous studies have reported conflicting results regarding the relationship of GCD and subsequent risk of developing breast cancer. This cohort study was conducted to investigate the association of GCD and breast cancer among women at high risk for breast cancer. METHODS: The Women At Risk Registry provided the study population. The variables of interest included age at enrollment, age at breast cancer diagnosis, body mass index (BMI), presence of lobular carcinoma in situ (LCIS), and Gail scores. Statistical significance was determined by calculating multivariable-adjusted rate ratios using Cox proportional hazards regression model with years of follow-up as the time scale. RESULTS: The study population included 1317 high-risk women, including 363 (28%) with GCD. The mean follow-up was 5.9 years for the GCD cohort, and 5.1 years for the non-GCD cohort (P < .001). The GCD and non-GCD groups differed by Gail score (P < .001), BMI (P < .01), presence of atypical hyperplasia (P < .001), presence of LCIS (P < .001), and family history of breast cancer (P < .001). Within the total population of 1317 women, 79 (6%) developed breast cancer; 28 (35%) out of the 79 had a prior history of GCD. Results from the Cox proportional hazards regression model showed a nonstatistically significant association of GCD and breast cancer (hazard ratio = 1.48, 95% confidence interval 0.88-2.51). The Kaplan-Meier overall survival estimate between the exposed and unexposed groups indicate that there are no differences in overall survival between the 2 groups (P = .5). CONCLUSIONS: These results do not support the contention that gross cystic disease is a significant risk factor for breast cancer.     

Serum levels of CEA and CA15-3 in different molecular subtypes and prognostic value in Chinese breast cancer

The prognostic significance of preoperative carcinoembryonic antigen (CEA) and cancer antigen 15-3 (CA15-3) levels in breast cancer is controversial. This study evaluated the prognostic value of preoperative serum CEA and CA15-3 levels in Chinese breast cancer patients. A total of 470 patients with breast cancer had preoperative CEA and CA15-3 concentrations measured. The relationships between preoperative concentration and clinicopathological factors and outcomes were determined. CEA and CA15-3 levels were increased in 34 (7.2%) and 58 (12.3%) patients, respectively. Elevations of serum CEA and CA-15-3 levels correlated with the primary tumor size and axillary lymph node status. CEA levels were lower in patients with triple-negative breast cancer than in those with other subtypes (P = 0.002). The 5-year distant metastasis-free survival (DMFS), disease-free survival (DFS), and overall survival (OS) of CEA-negative vs. CEA-positive patients were 84.1% vs. 54.5% (P < 0.001), 82.7% vs. 54.8% (P < 0.001), and 89.7% vs. 78.5% (P = 0.007), respectively. The 5-year DMFS, DFS, and OS of CA15-3-negative vs. CA15-3-positive patients were 84.0% vs. 69.6% (P = 0.002), 83.0% vs. 66.2% (P < 0.001), 90.9% vs. 74.2% (P = 0.005), respectively. Multivariate analysis of prognosis indicated that CEA and CA15-3 levels were independent prognostic factors for DMFS (P = 0.021) and DFS (P = 0.032), and DFS (P = 0.014) and OS (P = 0.032), respectively. Serum levels of CEA and CA15-3 may differ in breast cancer molecular subtypes and preoperative levels of CEA and CA15-3 have a significant effect on prognosis in Chinese women with breast cancer.     

GATA3 as a putative marker of breast cancer metastasis—A retrospective immunohistochemical study

Diagnostic verification of breast cancer metastasis with histopathology and imaging analysis is essential to determine tumor staging. The aim of this study was to validate the utility of GATA3 immunohistochemistry as a diagnostic marker for breast cancer metastases and metastases of unknown primary origin. Retrospective immunohistochemical analysis of GATA3 expression in 164 breast cancer metastases diagnosed between 2004 and 2014 showed a striking difference between mammaglobin and GATA3 expression (51.2% vs 94% positivity). These findings highlight GATA3 as a more reliable and sensitive diagnostic marker for breast cancer metastases and possibly metastatic tumors of unknown origin than mammaglobin.     

The clinical value of serum CA15-3 assay postoperatively in breast cancer patients

Serum carbohydrate antigen (CA15-3) values were examined in 300 normal subjects in order to determine the standard value of this antigen. The clinical relevance of repeatedly assaying this marker in patients with or without recurrent breast cancer postoperatively was compared with assaying the serum carcinoembryonic antigen (CEA) values. The upper limit of CA15-3 was calculated as being 25.3 U/ml in the normal subjects and the distributions of CA15-3 values were not markedly different among the normal subjects, even if they had been selected according to sex or age. Moreover, no differences were observed among normal women who had been randomly selected according to the age distribution of the breast cancer patients. Thirty samples taken from the breast cancer patients postoperatively revealed values of higher than 25 U/ml and 73 samples showed lower levels. The serum CEA values were positive in 16 samples and negative in 85 samples. Although the accuracy of the CEA assay was about 10 per cent higher than that of the CA15-3 assay, its low positive rate was unsatisfactory for effective use in the breast clinic. The results of this study suggest that serum CA15-3 is not detectable unless there is a relatively large number of tumor cells. The higher false positive rate of the CA15-3 assay should therefore be considered as suggesting recurrence.     

血清CEA、CA15-3及CA125检测对乳腺癌诊断价值的临床评价

乳腺癌是女性最常见的恶性肿瘤之一,目前发病率在女性恶性肿瘤中已高居第一位.我国乳腺癌的特点是发病年龄较早,早期多无症状,就诊时病期相对偏晚,出现转移致存活期较短,所以早期诊断、早期治疗是提高其生存率的关键.     

检测乳腺癌患者术后血清肿瘤指标的临床价值

目的 研究乳腺癌患者术后血清CA15-3、CEA和CA-125水平与乳腺癌各种临床资料以及病情转归的关系.方法 收集我院收治的临床信息完整的219例乳腺癌术后病例.应用化学发光免疫法检测血清CA15-3、CEA和CA-125浓度,统计分析其与各临床参数以及病情转归的关系.结果 乳腺癌转移时,血清CA15-3、CEA和CA-125水平均明显高于未转移组(P=0.000),且三项指标联合检测敏感性达64.1%.转移时血清CA-125和CA15-3水平与ER呈正相关(PCA-125=0.049,PCA15-3=0.039).多脏器转移者血清CA15-3、CEA和CA-125浓度明显高于单脏器转移者(P=0.000).远处转移病例CA15-3和CEA水平与局部复发病例存在统计学差异(PCA15-3=0.001,PCEA=0.022).结论 血清CA15-3、CEA和CA-125浓度升高与否是监测乳腺癌转移的有效指标.乳腺癌转移时血清CA15-3和(或)CA-125浓度升高可提示患者对内分泌治疗更敏感.     

Prognostic value of insulin-like growth factor 1 and insulin-like growth factor binding protein 3 blood levels in breast cancer

High circulating insulin-like growth factor 1 (IGF-1) levels are firmly established as a risk factor for developing breast cancer, especially estrogen positive tumors. The effect of circulating IGF-1 on prognosis once a tumor is established is unknown. The authors explored the effect of IGF-1 blood levels and of it's main binding protein, IGFBP-3, on overall survival and occurrence of second primary breast tumors in breast cancer patients, as well as reproductive and lifestyle factors that could modify this risk. Patients were accrued from six hospitals in the Netherlands between 1998 and 2003. Total IGF-1 and IGFBP-3 were measured in 582 plasma samples.No significant association between IGF-1 and IGFBP-3 plasma levels and overall survival was found. However, in a multivariate Cox regression model including standard prognostic variables high IGF-1 levels were related to worse overall survival in patients receiving endocrine therapy (HR = 1.37, 95% CI: 1.11, 1.69, P 0.004). These data at least indicate that higher IGF-1 levels, and as a consequence most likely IGF-1-induced signaling, are related to a less favorable overall survival in breast cancer patients treated with endocrine therapy. Interventions aimed at reducing circulating levels of IGF-1 in hormone receptor positive breast cancer may improve survival.     

细针穿刺细胞学检查对乳腺癌的诊断意义

目的 探讨细针穿刺细胞学检查对乳腺癌的诊断意义。方法 用带7号针头的一次性塑料5～10ml注射器，对439例病人的乳腺和腋下肿物进行细针穿刺细胞学检查，并与术后诊断作比较，观察其准确率。结果 本组病例作细针穿刺细胞学检查的准确率达97．2％。结论 细针穿刺细胞学检查安全、方便、准确率高，可作为乳腺癌的一种常规检查手段。     

Preoperative CA 15-3 levels predict the prognosis of nonmetastatic luminal A breast cancer

Background

The prognostic value of serum tumor markers (STMs) in nonmetastatic breast cancer patients with different molecular subtypes (luminal A, luminal B, and nonluminal) remains unknown. It is our institutional policy to assess the STMs in nonmetastatic patients. This retrospective single-center study is to investigate the association between STMs and clinical outcomes in nonmetastatic patients and the impact of molecular subtypes.

Methods

A total of 368 patients with available clinical outcomes, tumor node metastasis stages, and STMs levels were included. The serum level of preoperative STMs (carcinoembryonic antigen [CEA], cancer antigen 125 [CA-125], and cancer antigen 15-3 [CA 15-3]) was analyzed and compared among distinct molecular subtypes. Univariate and multivariate analyses were used to investigate the relationship among STMs concentrations and patient outcomes.

Results

The median levels of CA 15-3 were 10.2, 8.1 and 7.1 U/mL in patients with luminal A, luminal B, and nonluminal diseases, respectively (P = 0.015). The levels of CEA and CA-125 were similar among the subtypes. Multivariate analysis showed that higher CA 15-3 was significantly associated with worse clinical outcomes exclusively in luminal A patients (P = 0.033 for metastasis-free survival and P = 0.030 for relapse-free survival). In contrast, higher CEA was a significant prognostic factor for worse clinical outcomes (P = 0.003 for metastasis-free survival and P = 0.015 for metastasis-free survival) in nonluminal groups.

Conclusions

The prognostic value of preoperative STMs may be different among molecular subtypes. Patients with luminal A diseases had higher levels of CA 15-3. Higher preoperative CA 15-3 was associated with worse clinical outcomes exclusively in patients with luminal A diseases.